Selective Removal of Endometriotic Lesions Using CUSA Clarity in Ovarian Endometriomas
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age20+
SponsorKanazawa University
About this trial
This study aims to evaluate the feasibility and tissue selectivity of a novel surgical technology, the Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity, in the management of ovarian endometriomas. Ovarian endometriomas are cysts caused by endometriosis that can damage ovarian reserve when treated by conventional surgery. In this study, ovarian cyst wall specimens are examined ex vivo using different Tissue Select settings of the CUSA device. Histopathological analyses are performed to determine whether endometriotic epithelium can be selectively removed while preserving normal ovarian tissue. The findings may contribute to developing fertility-preserving surgical approaches for women with endometriomas.
Eligibility criteria
Qualifiers
Female patients diagnosed with ovarian endometrioma who undergo surgical treatment (cystectomy or adnexectomy) at Kanazawa University Hospital between January 1, 2025, and March 31, 2027.
Written informed consent obtained prior to study participation.
Age ≥ 20 years at the time of consent.
For patients with previously stored endometrioma specimens under a broad consent, additional written consent for participation in this study will be obtained.
Disqualifiers
Patients with suspected malignancy based on preoperative imaging.
Patients judged by the attending physician to be unsuitable for participation in this study for any reason.
Trial design
Treatments tested in this trial
- Cavitron Ultrasonic Surgical Aspirator (CUSA) Clarity
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov